<DOC>
	<DOCNO>NCT01551615</DOCNO>
	<brief_summary>Study Healthy Volunteers Assess Pharmacokinetics Metformin Administered Alone In Combination Vandetanib</brief_summary>
	<brief_title>A Phase I Study Assess Pharmacokinetics Metformin When Administered Alone Combination With Vandetanib</brief_title>
	<detailed_description>A Phase I , Open-label , Single-center Study Assess Pharmacokinetics Metformin , OCT2 Substrate , Healthy Subjects When administer Alone Combination Single Oral Dose Vandetanib ( CAPRELSA ) 800 mg</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male female age 18 50 year weight least 50 kg body mass index 18 30 kg/m2 inclusive . Females must negative pregnancy test screening , must lactate must nonchildbearing potential . Volunteers wild type OCT2 gene ( test within last 6 month prior Day 1 Period 1 ) History presence gastrointestinal , hepatic , renal disease medically significant disorder . History ongoing severe allergy/hypersensitivity drug similar chemical structure class vandetanib metformin . Volunteers smoke 5 cigarette per day unable refrain smoking resident study center . Known suspected history drug abuse . Screening supine blood pressure great 140/90 mmHg and/or rest heart rate le 45 beat per minute . Clinically significant current active skin disease ( eg moderate severe acne , psoriasis , eczema ) . Any positive result screen serum hepatitis B , surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>vandetanib</keyword>
	<keyword>metformin</keyword>
	<keyword>AUC ( 0-t )</keyword>
	<keyword>t1/2</keyword>
	<keyword>tmax</keyword>
	<keyword>CL/F</keyword>
	<keyword>Vz/F</keyword>
	<keyword>Cmax</keyword>
</DOC>